These companies have positioned themselves to provide a generous and rising income stream.
Compare ABBV Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: AbbVie
The Oracle of Omaha is largely a set-and-forget kind of investor and you should be, too.
They all pay more than double what you'll get with the average stock in the S&P 500.
A regulatory setback weighed on the drugmaker's shares last month.
Building an intuitive understanding of these warning signs is critical for success with pharma stocks.
The well-known pharmaceutical company is a portfolio stalwart.
The big drugmaker wants another near-term growth driver.
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.
Probably so -- for some investors.
The market has written off these two high-quality stocks, but both could complement an income investor's portfolio.